StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q2 2026
24
Period ended Jun 30, 2026
Change on a year earlier
-36.8%
38 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
34
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIsentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202624-36.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202624-38.5%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 202530-43.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202537-22.9%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202538-17.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202539-36.1%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202453-5.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202448-21.3%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202446-42.5%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202461-14.1%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202356-37.1%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202361-34.4%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023800.0%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202371-26.8%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202289-16.0%Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 202293-17.0%Form 10-Q (filed 2023-11-03) ↗

Breakdown

What makes up isentress / isentress hd (raltegravir — hiv-1 integrase inhibitor) — international sales ($m)

Cite this data

StockData. (2026). Merck Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International sales ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_isentress_intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.